{"id":1068045,"date":"2020-11-05T09:55:53","date_gmt":"2020-11-05T14:55:53","guid":{"rendered":"https:\/\/www.immortalitymedicine.tv\/genmab-announces-phase-3-study-evaluating-epcoritamab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma\/"},"modified":"2024-08-18T11:42:17","modified_gmt":"2024-08-18T15:42:17","slug":"genmab-announces-phase-3-study-evaluating-epcoritamab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma","status":"publish","type":"post","link":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/genmab-announces-phase-3-study-evaluating-epcoritamab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.php","title":{"rendered":"Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma"},"content":{"rendered":"<p><![CDATA[Company Announcement]]><\/p>\n<p>Go here to see the original:<br \/>\n<a target=\"_blank\" rel=\"nofollow noopener noreferrer\" href=\"http:\/\/www.globenewswire.com\/news-release\/2020\/11\/05\/2121107\/0\/en\/Genmab-Announces-Phase-3-Study-Evaluating-Epcoritamab-in-Patients-with-Relapsed-or-Refractory-Diffuse-Large-B-cell-Lymphoma.html?f=22&amp;fvtc=5&amp;fvtv=46634288\" title=\"Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma\">Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Go here to see the original: Genmab Announces Phase 3 Study Evaluating Epcoritamab in Patients with Relapsed or Refractory Diffuse Large B-cell Lymphoma <a href=\"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/global-news-feed\/genmab-announces-phase-3-study-evaluating-epcoritamab-in-patients-with-relapsed-or-refractory-diffuse-large-b-cell-lymphoma.php\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":64,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"limit_modified_date":"","last_modified_date":"","_lmt_disableupdate":"","_lmt_disable":"","footnotes":""},"categories":[1246886],"tags":[],"class_list":["post-1068045","post","type-post","status-publish","format-standard","hentry","category-global-news-feed"],"modified_by":null,"_links":{"self":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068045"}],"collection":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/users\/64"}],"replies":[{"embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/comments?post=1068045"}],"version-history":[{"count":0,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/posts\/1068045\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/media?parent=1068045"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/categories?post=1068045"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.euvolution.com\/futurist-transhuman-news-blog\/wp-json\/wp\/v2\/tags?post=1068045"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}